ImmunityBio [IBRX] vs Regeneron [REGN] Detailed Stock Comparison
ImmunityBio
NASDAQ
Loading...
Regeneron
NASDAQ
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: ImmunityBio wins in 9 metrics, Regeneron wins in 9 metrics, with 0 ties. Both stocks appear equally matched on key metrics.
View Metrics Details
Vital Metrics Comparison
| Metric | ImmunityBio | Regeneron | Better |
|---|---|---|---|
| P/E Ratio (TTM) | -4.31 | 15.13 | ImmunityBio |
| Price-to-Book Ratio | -3.96 | 2.09 | ImmunityBio |
| Debt-to-Equity Ratio | -1.48 | 9.04 | ImmunityBio |
| PEG Ratio | 0.09 | -200.46 | Regeneron |
| EV/EBITDA | -11.49 | 12.86 | ImmunityBio |
| Profit Margin (TTM) | 100.00% | 31.37% | ImmunityBio |
| Operating Margin (TTM) | -269.76% | 29.64% | Regeneron |
| EBITDA Margin (TTM) | N/A | 29.64% | N/A |
| Return on Equity | 84.72% | 15.34% | ImmunityBio |
| Return on Assets (TTM) | -42.14% | 6.66% | Regeneron |
| Free Cash Flow (TTM) | $-398.12M | $3.54B | Regeneron |
| Dividend Yield | N/A | 0.46% | N/A |
| 1-Year Return | -30.68% | -42.36% | ImmunityBio |
| Price-to-Sales Ratio (TTM) | 42.42 | 4.47 | Regeneron |
| Enterprise Value | $3.09B | $57.45B | Regeneron |
| EV/Revenue Ratio | 54.61 | 4.04 | Regeneron |
| Gross Profit Margin (TTM) | 99.49% | 85.58% | ImmunityBio |
| Revenue per Share (TTM) | $0 | $133 | Regeneron |
| Earnings per Share (Diluted) | $-0.48 | $39.66 | Regeneron |
| Beta (Stock Volatility) | -0.06 | 0.31 | ImmunityBio |
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends
ImmunityBio vs Regeneron Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| ImmunityBio | -0.39% | -1.56% | 4.98% | -6.99% | -6.99% | -1.56% |
| Regeneron | -2.42% | 4.41% | 4.84% | 8.80% | 2.22% | -18.14% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| ImmunityBio | -30.68% | -48.79% | -72.56% | -80.09% | -91.73% | -91.73% |
| Regeneron | -42.36% | -20.46% | -2.38% | 13.78% | 1,988.02% | 6,243.23% |
News Based Sentiment: ImmunityBio vs Regeneron
ImmunityBio
News based Sentiment: MIXED
October brought a mix of positive and negative developments for ImmunityBio, including regulatory approvals, promising clinical trial data, a significant financing round, but also a setback with an sBLA filing and a high valuation. These events collectively represent a significant month for the company and its investors.
Regeneron
News based Sentiment: POSITIVE
October proved to be a positive month for Regeneron, marked by key FDA approvals for Lynozyfic and Evkeeza, encouraging trial results for their obesity pipeline, and positive analyst coverage from JP Morgan and Morningstar. While the Eylea biosimilar settlement introduces a future challenge, the overall narrative points towards continued growth and potential value for investors.
Performance & Financial Health Analysis: ImmunityBio vs Regeneron
| Metric | IBRX | REGN |
|---|---|---|
| Market Information | ||
| Market Cap | $2.49B | $63.78B |
| Market Cap Category | Mid cap | Large cap |
| 10 Day Avg. Volume | 8,037,890 | 1,129,150 |
| 90 Day Avg. Volume | 9,879,247 | 1,040,977 |
| Last Close | $2.53 | $585.48 |
| 52 Week Range | $1.83 - $7.48 | $476.49 - $1,024.36 |
| % from 52W High | -66.18% | -42.84% |
| All-Time High | $45.42 (Feb 22, 2021) | $1,211.20 (Aug 26, 2024) |
| % from All-Time High | -94.43% | -51.66% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 24.24% | 0.04% |
| Quarterly Earnings Growth | 24.24% | -0.03% |
| Financial Health | ||
| Profit Margin (TTM) | 1.00% | 0.31% |
| Operating Margin (TTM) | -2.70% | 0.30% |
| Return on Equity (TTM) | 0.85% | 0.15% |
| Debt to Equity (MRQ) | -1.48 | 9.04 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $-0.62 | $287.55 |
| Cash per Share (MRQ) | $0.16 | $72.04 |
| Operating Cash Flow (TTM) | $-349,558,016 | $4.74B |
| Levered Free Cash Flow (TTM) | $-249,235,872 | $2.85B |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | 0.46% |
| Last 12-Month Dividend | N/A | $2.64 |
Valuation & Enterprise Metrics Analysis: ImmunityBio vs Regeneron
| Metric | IBRX | REGN |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | -4.31 | 15.13 |
| Forward P/E | -4.03 | 13.24 |
| PEG Ratio | 0.09 | -200.46 |
| Price to Sales (TTM) | 42.42 | 4.47 |
| Price to Book (MRQ) | -3.96 | 2.09 |
| Market Capitalization | ||
| Market Capitalization | $2.49B | $63.78B |
| Enterprise Value | $3.09B | $57.45B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 54.61 | 4.04 |
| Enterprise to EBITDA | -11.49 | 12.86 |
| Risk & Other Metrics | ||
| Beta | -0.06 | 0.31 |
| Book Value per Share (MRQ) | $-0.62 | $287.55 |
Financial Statements Comparison: ImmunityBio vs Regeneron
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | IBRX | REGN |
|---|---|---|
| Revenue/Sales | $16.52M | $3.03B |
| Cost of Goods Sold | $58,000 | $464.30M |
| Gross Profit | $16.46M | $2.56B |
| Research & Development | $48.23M | $1.34B |
| Operating Income (EBIT) | $-64.43M | $591.70M |
| EBITDA | $-102.70M | $900.90M |
| Pre-Tax Income | $-129.90M | $905.00M |
| Income Tax | $-234,000 | $96.30M |
| Net Income (Profit) | $-129.67M | $808.70M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | IBRX | REGN |
|---|---|---|
| Cash & Equivalents | $60.66M | $3.09B |
| Total Current Assets | $109.16M | $17.57B |
| Total Current Liabilities | $49.21M | $3.57B |
| Long-Term Debt | $518.81M | $2.70B |
| Total Shareholders Equity | $-590.48M | $29.39B |
| Retained Earnings | $-3.50B | $32.38B |
| Property, Plant & Equipment | $106.70M | N/A |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | IBRX | REGN |
|---|---|---|
| Operating Cash Flow | $-35.91M | $1.36B |
| Capital Expenditures | $-1.08M | N/A |
| Free Cash Flow | $-80.83M | $773.60M |
| Debt Repayment | $-4,000 | N/A |
| Common Stock Repurchase | N/A | $-1.05B |
Short Interest & Institutional Ownership Analysis
| Metric | IBRX | REGN |
|---|---|---|
| Shares Short | 84.56M | 2.99M |
| Short Ratio | 8.53 | 3.06 |
| Short % of Float | 0.29% | 0.03% |
| Average Daily Volume (10 Day) | 8,037,890 | 1,129,150 |
| Average Daily Volume (90 Day) | 9,879,247 | 1,040,977 |
| Shares Outstanding | 852.90M | 109.62M |
| Float Shares | 193.56M | 97.89M |
| % Held by Insiders | 0.69% | 0.02% |
| % Held by Institutions | 0.13% | 0.90% |
Dividend Analysis & Yield Comparison: ImmunityBio vs Regeneron
| Metric | IBRX | REGN |
|---|---|---|
| Last 12-Month Dividend | N/A | $2.64 |
| Last 12-Month Dividend Yield | N/A | 0.46% |
| 3-Year Avg Annual Dividend | N/A | $0.88 |
| 3-Year Avg Dividend Yield | N/A | 0.14% |
| 3-Year Total Dividends | N/A | $2.64 |
| Ex-Dividend Date | N/A | Aug 18, 2025 |